(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -4.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.4%.
Arcus Biosciences's revenue in 2026 is $247,000,000.On average, 13 Wall Street analysts forecast RCUS's revenue for 2026 to be $11,798,143,380, with the lowest RCUS revenue forecast at $859,897,405, and the highest RCUS revenue forecast at $28,955,728,956. On average, 13 Wall Street analysts forecast RCUS's revenue for 2027 to be $17,180,399,181, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $46,651,314,483.
In 2028, RCUS is forecast to generate $28,216,167,048 in revenue, with the lowest revenue forecast at $9,818,624,455 and the highest revenue forecast at $77,749,265,984.